Titan Pharmaceuticals (NASDAQ: TTNP) is one of 106 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Titan Pharmaceuticals to related companies based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, dividends and profitability.
Institutional and Insider Ownership
12.2% of Titan Pharmaceuticals shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 19.5% of Titan Pharmaceuticals shares are held by insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Titan Pharmaceuticals has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals’ peers have a beta of 1.64, suggesting that their average share price is 64% more volatile than the S&P 500.
This table compares Titan Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Titan Pharmaceuticals Competitors||-8,316.86%||-75.40%||-24.08%|
Earnings and Valuation
This table compares Titan Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Titan Pharmaceuticals||$220,000.00||-$14.30 million||-0.57|
|Titan Pharmaceuticals Competitors||$1.02 billion||$93.10 million||-4.69|
Titan Pharmaceuticals’ peers have higher revenue and earnings than Titan Pharmaceuticals. Titan Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations and price targets for Titan Pharmaceuticals and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Titan Pharmaceuticals Competitors||641||2219||5389||219||2.61|
Titan Pharmaceuticals currently has a consensus price target of $2.00, suggesting a potential upside of 399.25%. As a group, “Biological products, except diagnostic” companies have a potential upside of 35.14%. Given Titan Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Titan Pharmaceuticals is more favorable than its peers.
Titan Pharmaceuticals peers beat Titan Pharmaceuticals on 9 of the 13 factors compared.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.